MetaCap

Biohaven (BHVN) vs Harmony Biosciences (HRMY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biohaven (BHVN) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 27.9% versus a loss of 5.0%. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.87 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHVN+27.86%HRMY-5.01%
+80%+26%-28%
Nov 21, 20251 yearNov 20, 2026
BHVN+73.63%HRMY-23.26%
+751%+329%-93%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHVN versus HRMY key metrics
MetricBHVNHRMY
Share price$12.39$32.59
Market cap$1.87B$1.91B
1-day change-9.23%-1.18%
YTD return+9.74%-12.91%
1-year return+27.86%-5.01%
5-year return—-13.21%
P/E ratio (TTM)—10.79
Forward P/E—5.37
EPS (TTM)$-3.77$3.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$868.45M
Revenue growth (YoY)—+21.51%
Net income (latest FY)$-738.82M$158.69M
Gross margin—77.16%
Operating margin—24.00%
Net margin—18.27%
52-week high$18.24$43.49
52-week low$8.03$25.90
Distance from 52-week high-32.07%-25.06%
Analyst consensusbuybuy
Avg. price target upside+102.82%+47.53%
Average volume3.24M1.01M
Shares outstanding151.06M58.72M
Employees274293
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHVN has outperformed HRMY by 32.9 percentage points over the past year.

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

About Harmony Biosciences

HRMY stock →

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

BHVN vs HRMY FAQ

Which is bigger, Biohaven or Harmony Biosciences?

Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.87B for Biohaven (BHVN).

Which stock has performed better over the past year, BHVN or HRMY?

BHVN returned +27.86% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.

Are Biohaven and Harmony Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons